Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data
P ublished: Mar 09, 2023 By Kate Goodwin Pictured: Clene CEO Rob Etherington/company courtesy Despite missing the initial mark, Clene Inc.’s gold nanocrystal therapy for ALS still shows promise. Thursday, the company shared new results from an exploratory analysis showing CNM-Au8 delayed disease progression across key areas for patients. In October 2022, Clene reported that CNM-Au8 did not meet the primary endpoint of slope of change in the HEALEY ALS trial based on the adjusted ALS Functional Rating Scale-Revised. However, the strong survival signals seen at six months warranted a deeper look. Original article